Oral Manifestations of Glucagon-Like Peptide-1 Receptor Agonist Therapy: Implications for Dental Practice

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the management of type 2 diabetes mellitus and obesity, becoming among the most widely prescribed pharmacologic therapies worldwide. Medications such as semaglutide, tirzepatide, liraglutide, dulaglutide, and exenatide have demonstrated substantial benefits in glycemic control, weight reduction, and cardiovascular risk reduction. As the use of these agents continues to expand, healthcare providers are increasingly recognizing adverse effects that extend beyond the gastrointestinal and metabolic systems. Emerging evidence suggests that GLP-1 receptor agonists may influence oral health through alterations in salivary gland function, delayed gastric emptying, reflux-related complications, dehydration, and changes in nutritional status. Reports of xerostomia, halitosis, taste disturbances, enamel erosion, dentinal hypersensitivity, and increased caries susceptibility have generated growing interest within the dental community. Emerging literature has also explored the potential impact of GLP-1 therapy on periodontal health, peri-implant tissues, and oral inflammatory processes.
This narrative review examines the pharmacologic basis of GLP-1 receptor agonists and discusses their potential oral manifestations and implications for dental practice. Particular emphasis is placed on xerostomia, dental erosion, caries risk, oral mucosal changes, periodontal considerations, and the emerging concept of “Ozempic mouth.” The review also highlights clinical recommendations for dental professionals managing patients receiving GLP-1 receptor agonist therapy and identifies areas requiring future investigation. As the use of these medications continues to increase, dental practitioners must recognize potential oral complications and implement preventive strategies to optimize patient outcomes.

GLP-1 receptor agonists, semaglutide, tirzepatide, oral manifestations, xerostomia, dental erosion, oral health, obesity, diabetes, dentistry

1. Kalra S, Das S, Zargar AH. A Review of Oral Semaglutide Available Evidence: A New Era of Management of Diabetes with Peptide in a Pill Form. Indian J Endocrinol Metab. 2022;26(2):98-105. [Google Scholar] [Crossref]

2. Jena S, Jindal R, Dutta D, Mohammad Kamrul-Hasan A, Mahajan K. Efficacy and Safety of Oral Semaglutide in the Management of Diabetes and Obesity: A Comprehensive Meta-analysis of Real-world Evidence. touchREV Endocrinol. 2026;22(1):16-28. [Google Scholar] [Crossref]

3. Glucagon-like peptide-1 receptor agonists: a review of the impact on the facial profile and oral cavity and relevance to dental practice. Br Dent J. 2025. [Google Scholar] [Crossref]

4. Barać M, Roganović J. GLP-1 Receptor Signaling and Oral Dysfunction: A Narrative Review on the Mechanistic Basis of Semaglutide-Related Oral Adverse Effects. Biology (Basel). 2025;14(12):1650. [Google Scholar] [Crossref]

5. Glucagon-like peptide-1 receptor agonists and oral health. Br Dent J. 2026. [Google Scholar] [Crossref]

6. Adverse Events of Oral GLP-1 Receptor Agonist (Semaglutide): A Pharmacovigilance Study Based on FDA Adverse Event Reporting System. Diabetes Ther. 2024. [Google Scholar] [Crossref]

7. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989-1002. [Google Scholar] [Crossref]

8. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205-216. [Google Scholar] [Crossref]

9. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756. [Google Scholar] [Crossref]

10. Nauck MA, Müller TD. Incretin hormones and type 2 diabetes. Diabetologia. 2023;66:1785-1799. [Google Scholar] [Crossref]

11. Marathe CS, Rayner CK, Jones KL, Horowitz M. Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function. Exp Diabetes Res. 2011;2011:279530. [Google Scholar] [Crossref]

12. Villa A, Wolff A, Narayana N, Dawes C, Aframian D, Lynge Pedersen A, et al. World Workshop on Oral Medicine VI: A systematic review of medication-induced salivary gland dysfunction. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;120(2):185-206. [Google Scholar] [Crossref]

13. Dawes C, Pedersen AML, Villa A, Ekström J, Proctor GB, Vissink A, et al. The Functions of Human Saliva: A Review. Arch Oral Biol. 2015;60(6):863-874. [Google Scholar] [Crossref]

14. Edgar WM. Saliva: Its Secretion, Composition and Functions. Br Dent J. 1992;172(8):305-312. [Google Scholar] [Crossref]

15. Ship JA, Fox PC, Baum BJ. How Much Saliva Is Enough? Normal Function Defined. J Am Dent Assoc. 1991;122(3):63-69. [Google Scholar] [Crossref]

16. Villa A, Connell CL, Abati S. Diagnosis and Management of Xerostomia and Hyposalivation. Ther Clin Risk Manag. 2015;11:45-51. [Google Scholar] [Crossref]

17. Bartlett DW, Smith BGN. Dental Erosion: The Diagnosis and Management of Erosive Tooth Wear. Br Dent J. 1996;180(5):175-179. [Google Scholar] [Crossref]

18. Lussi A, Schlueter N, Rakhmatullina E, Ganss C. Dental Erosion—An Overview with Emphasis on Chemical and Histopathological Aspects. Caries Res. 2011;45(Suppl 1):2-12. [Google Scholar] [Crossref]

19. Sculean A, Chapple ILC, Giannobile WV. Wound Models for Periodontal and Implant Research. Periodontol 2000. 2019;79(1):7-20. [Google Scholar] [Crossref]

20. Preshaw PM, Alba AL, Herrera D, Jepsen S, Konstantinidis A, Makrilakis K, et al. Periodontitis and Diabetes: A Two-Way Relationship. Diabetologia. 2012;55(1):21-31. [Google Scholar] [Crossref]

21. Sanz M, Ceriello A, Buysschaert M, Chapple I, Demmer RT, Graziani F, et al. Scientific Evidence on the Links Between Periodontal Diseases and Diabetes. J Clin Periodontol. 2018;45(2):138-149. [Google Scholar] [Crossref]

22. World Health Organization. Obesity and Overweight. Geneva: World Health Organization; 2025. [Google Scholar] [Crossref]

23. American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1). [Google Scholar] [Crossref]

• Assessment of the Role of Artificial Intelligence in Repositioning TVET for Economic Development in Nigeria
• Teachers’ Use of Assure Model Instructional Design on Learners’ Problem Solving Efficacy in Secondary Schools in Bungoma County, Kenya
• “E-Booksan Ang Kaalaman”: Development, Validation, and Utilization of Electronic Book in Academic Performance of Grade 9 Students in Social Studies
• Analyzing EFL University Students’ Academic Speaking Skills Through Self-Recorded Video Presentation
• Major Findings of The Study on Total Quality Management in Teachers’ Education Institutions (TEIs) In Assam – An Evaluative Study